View ValuationLenzing 将来の成長Future 基準チェック /06Lenzing利益と収益がそれぞれ年間71.2%と1.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-3.9% 80.9%なると予測されています。主要情報71.2%収益成長率80.92%EPS成長率Chemicals 収益成長20.3%収益成長率1.9%将来の株主資本利益率-3.91%アナリストカバレッジLow最終更新日07 May 2026今後の成長に関する最新情報Price Target Changed • Apr 07Price target decreased by 10.0% to €23.50Down from €26.10, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of €23.05. Stock is down 4.4% over the past year. The company is forecast to post a net loss per share of €1.83 next year compared to a net loss per share of €5.45 last year.Major Estimate Revision • Feb 18Consensus EPS estimates fall by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€3.34 to -€3.88 per share. Revenue forecast unchanged at €2.62b. Chemicals industry in Austria expected to see average net income growth of 29% next year. Consensus price target broadly unchanged at €26.10. Share price fell 5.8% to €26.10 over the past week.Breakeven Date Change • Feb 17No longer forecast to breakevenThe 5 analysts covering Lenzing no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €49.9m in 2027. New consensus forecast suggests the company will make a loss of €60.8m in 2027.Price Target Changed • Dec 29Price target decreased by 11% to €24.50Down from €27.40, the current price target is an average from 4 analysts. New target price is 8.9% above last closing price of €22.50. Stock is down 24% over the past year. The company is forecast to post a net loss per share of €3.34 next year compared to a net loss per share of €4.06 last year.Major Estimate Revision • Oct 01Consensus EPS estimates fall by 38%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€1.37 to -€1.89 per share. Revenue forecast of €2.69b unchanged since last update. Chemicals industry in Austria expected to see average net income growth of 17% next year. Consensus price target broadly unchanged at €28.20. Share price fell 3.7% to €25.80 over the past week.Major Estimate Revision • Aug 15Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.988 to -€1.10 per share. Revenue forecast unchanged at €2.69b. Chemicals industry in Austria expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at €28.60. Share price fell 5.5% to €26.75 over the past week.すべての更新を表示Recent updatesPrice Target Changed • Apr 07Price target decreased by 10.0% to €23.50Down from €26.10, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of €23.05. Stock is down 4.4% over the past year. The company is forecast to post a net loss per share of €1.83 next year compared to a net loss per share of €5.45 last year.Reported Earnings • Mar 20Full year 2025 earnings released: €5.45 loss per share (vs €4.06 loss in FY 2024)Full year 2025 results: €5.45 loss per share (further deteriorated from €4.06 loss in FY 2024). Revenue: €2.60b (down 2.3% from FY 2024). Net loss: €210.3m (loss widened 34% from FY 2024). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.Major Estimate Revision • Feb 18Consensus EPS estimates fall by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€3.34 to -€3.88 per share. Revenue forecast unchanged at €2.62b. Chemicals industry in Austria expected to see average net income growth of 29% next year. Consensus price target broadly unchanged at €26.10. Share price fell 5.8% to €26.10 over the past week.Breakeven Date Change • Feb 17No longer forecast to breakevenThe 5 analysts covering Lenzing no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €49.9m in 2027. New consensus forecast suggests the company will make a loss of €60.8m in 2027.お知らせ • Feb 03Lenzing Aktiengesellschaft (WBAG:LNZ) acquired an additional unknown minority stake in TreeToTextile AB.Lenzing Aktiengesellschaft (WBAG:LNZ) acquired an additional unknown minority stake in TreeToTextile AB on February 2, 2026. The transaction is executed through the issuance of new shares. After the acquisition Lenzing Aktiengesellschaft will own majority stake in TreeToTextile AB. Lenzing Aktiengesellschaft (WBAG:LNZ) completed the acquisition of additional unknown minority stake in TreeToTextile AB on February 2, 2026.Price Target Changed • Dec 29Price target decreased by 11% to €24.50Down from €27.40, the current price target is an average from 4 analysts. New target price is 8.9% above last closing price of €22.50. Stock is down 24% over the past year. The company is forecast to post a net loss per share of €3.34 next year compared to a net loss per share of €4.06 last year.お知らせ • Dec 09Lenzing Aktiengesellschaft, Annual General Meeting, Apr 23, 2026Lenzing Aktiengesellschaft, Annual General Meeting, Apr 23, 2026.Major Estimate Revision • Oct 01Consensus EPS estimates fall by 38%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€1.37 to -€1.89 per share. Revenue forecast of €2.69b unchanged since last update. Chemicals industry in Austria expected to see average net income growth of 17% next year. Consensus price target broadly unchanged at €28.20. Share price fell 3.7% to €25.80 over the past week.お知らせ • Sep 02+ 3 more updatesLenzing Aktiengesellschaft to Report Q1, 2026 Results on May 07, 2026Lenzing Aktiengesellschaft announced that they will report Q1, 2026 results on May 07, 2026Major Estimate Revision • Aug 15Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.988 to -€1.10 per share. Revenue forecast unchanged at €2.69b. Chemicals industry in Austria expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at €28.60. Share price fell 5.5% to €26.75 over the past week.Price Target Changed • Aug 12Price target decreased by 8.9% to €28.50Down from €31.28, the current price target is an average from 5 analysts. New target price is 7.5% above last closing price of €26.50. Stock is down 13% over the past year. The company is forecast to post a net loss per share of €1.16 next year compared to a net loss per share of €4.06 last year.Reported Earnings • Aug 08Second quarter 2025 earnings released: €1.02 loss per share (vs €1.01 loss in 2Q 2024)Second quarter 2025 results: €1.02 loss per share (further deteriorated from €1.01 loss in 2Q 2024). Revenue: €650.9m (flat on 2Q 2024). Net loss: €39.4m (loss widened 1.0% from 2Q 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 31% per year and the company’s share price has also fallen by 31% per year.分析記事 • Aug 01Returns On Capital At Lenzing (VIE:LNZ) Paint A Concerning PictureDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Major Estimate Revision • Jul 09Consensus EPS estimates fall by 18%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.835 to -€0.988 per share. Revenue forecast unchanged at €2.69b. Chemicals industry in Austria expected to see average net income growth of 20% next year. Consensus price target broadly unchanged at €30.95. Share price rose 2.8% to €25.50 over the past week.分析記事 • Jul 09Lenzing Aktiengesellschaft's (VIE:LNZ) Low P/S No Reason For ExcitementWhen close to half the companies operating in the Chemicals industry in Austria have price-to-sales ratios (or "P/S...Price Target Changed • Jul 08Price target decreased by 7.5% to €30.95Down from €33.45, the current price target is an average from 6 analysts. New target price is 23% above last closing price of €25.10. Stock is down 24% over the past year. The company is forecast to post a net loss per share of €0.99 next year compared to a net loss per share of €4.06 last year.Major Estimate Revision • Jun 17Consensus EPS estimates fall by 38%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.604 to -€0.835 per share. Revenue forecast unchanged at €2.70b. Chemicals industry in Austria expected to see average net income growth of 18% next year. Consensus price target down from €33.45 to €31.28. Share price fell 12% to €23.75 over the past week.分析記事 • Jun 12Does Lenzing (VIE:LNZ) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Major Estimate Revision • Jun 01Consensus EPS estimates fall by 25%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.484 to -€0.604 per share. Revenue forecast unchanged at €2.72b. Chemicals industry in Austria expected to see average net income growth of 17% next year. Consensus price target of €33.45 unchanged from last update. Share price was steady at €26.40 over the past week.Reported Earnings • May 13First quarter 2025 earnings released: EPS: €0.12 (vs €0.83 loss in 1Q 2024)First quarter 2025 results: EPS: €0.12 (up from €0.83 loss in 1Q 2024). Revenue: €690.2m (up 4.8% from 1Q 2024). Net income: €4.70m (up €36.7m from 1Q 2024). Profit margin: 0.7% (up from net loss in 1Q 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.お知らせ • Apr 18Lenzing Announces Supervisory Board ChangesLenzing at its annual general meeting, appointed Patrick Lackenbucher and Leonardo Grimaldi to the supervisory board until 2029. They replace Cord Prinzhorn, whose term expired, and Marcelo Feriozzi Bacci, who resigned from the board in December 2024, according to a company statement on Thursday.分析記事 • Apr 14Returns On Capital Signal Tricky Times Ahead For Lenzing (VIE:LNZ)If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...お知らせ • Apr 03The Lenzing Group Announces Board Member and Chief Transformation Officer Walter Bickel Will Leave Company At the End of March 2025The Lenzing Group announced personnel changes in the company’s Managing Board. The Supervisory Board of Lenzing AG and Dr. Walter Bickel, Chief Transformation Officer of Lenzing AG, have mutually agreed to end the temporary mandate of Mr. Bickel and that Mr. Bickel will step down from his operational activities at the end of March 2025. Mr. Bickel was appointed to the Managing Board of Lenzing AG as of April 15, 2024 to strengthen the Lenzing Managing Board and to be responsible for the further development and implementation of the performance program. Under his leadership, a significant overachievement of the planned contributions from the performance program could be realized. The basis for future significant improvement steps is established, and the program has been structured in a way that it can now be continued by Lenzing AG seamlessly.Major Estimate Revision • Apr 02Consensus EPS estimates upgraded to €0.49 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -€0.64 to -€0.487 per share. Revenue forecast steady at €2.72b. Chemicals industry in Austria expected to see average net income growth of 17% next year. Consensus price target broadly unchanged at €32.95. Share price fell 15% to €25.90 over the past week.分析記事 • Mar 15Lenzing Aktiengesellschaft (VIE:LNZ) Surges 35% Yet Its Low P/S Is No Reason For ExcitementLenzing Aktiengesellschaft ( VIE:LNZ ) shares have had a really impressive month, gaining 35% after a shaky period...Reported Earnings • Mar 14Full year 2024 earnings released: €4.06 loss per share (vs €20.02 loss in FY 2023)Full year 2024 results: €4.06 loss per share (improved from €20.02 loss in FY 2023). Revenue: €2.66b (up 5.7% from FY 2023). Net loss: €156.6m (loss narrowed 76% from FY 2023). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.お知らせ • Mar 12Cord Prinzhorn Not Stand for Re-Election as Member of Lenzing AG's Supervisory BoardThe Chairman of the Supervisory Board of Lenzing AG, Cord Prinzhorn, has informed the Nomination Committee of the Supervisory Board that he will not extend his term as a member of the company’s Supervisory Board after the Annual General Meeting on April 17, 2025 and will not stand for re-election at the upcoming Annual General Meeting. Cord Prinzhorn intends to devote more time to his existing and new activities at the B&C Group. Mr. Prinzhorn will thus leave the Supervisory Board of Lenzing AG at the end of the Annual General Meeting.New Risk • Feb 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Austrian stocks, typically moving 6.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (6.0% average weekly change).お知らせ • Jan 27Lenzing Aktiengesellschaft, Annual General Meeting, Apr 17, 2025Lenzing Aktiengesellschaft, Annual General Meeting, Apr 17, 2025.分析記事 • Jan 14Is Lenzing (VIE:LNZ) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (4.6% average weekly change).分析記事 • Dec 06Investors Don't See Light At End Of Lenzing Aktiengesellschaft's (VIE:LNZ) TunnelWhen you see that almost half of the companies in the Chemicals industry in Austria have price-to-sales ratios (or...Major Estimate Revision • Nov 14Consensus EPS estimates fall by 34%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -€2.63 to -€3.51 per share. Revenue forecast unchanged at €2.66b. Chemicals industry in Austria expected to see average net income growth of 35% next year. Consensus price target broadly unchanged at €33.74. Share price fell 5.6% to €29.75 over the past week.Reported Earnings • Nov 08Third quarter 2024 earnings released: €1.66 loss per share (vs €0.97 loss in 3Q 2023)Third quarter 2024 results: €1.66 loss per share (further deteriorated from €0.97 loss in 3Q 2023). Revenue: €647.5m (up 5.2% from 3Q 2023). Net loss: €64.1m (loss widened 45% from 3Q 2023). Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.お知らせ • Nov 06Lenzing Nonwovens Expands its LENZING Lyocell Dry Fiber Portfolio to Offer Cellulosic Solutions for a Wider Range of ApplicationsLenzing Nonwovens announced the expansion of its LENZING Lyocell Dry fiber portfolio with two new cellulosic fibers – a fine dry fiber that delivers strength and softness and a coarse dry fiber which provides enhanced liquid and air flow. These two innovative products enable customers to confidently broaden their use of LENZING's wood-based and biodegradable fibers into a wider range of applications while maintaining exceptional performance. All LENZING Lyocell Dry fibers within the family (standard, fine, and coarse) have hydrophobic properties which ensure efficient liquid management suitable for extensive nonwoven applications. The new LENZING Lyocell Dry fine fiber can produce nonwoven fabrics with higher density compared to LENZING Lyocell Dry standard fiber. With up to 30% more cellulosic fibers in the same space, customers can create strong and soft nonwoven products. These fibers are suitable for use in hygiene applications such as diapers or sanitary pads. The new LENZING Lyocell Dry coarse fiber creates fabrics that are more open due to its extended fiber diameter, and thus increasing the pore sizes between the fibers in the fabric. This allows for more air or liquid to flow through the material. It is particularly suitable for the acquisition and distribution layer in hygiene products and is also being explored for industrial filtration applications. Lenzing will showcase its innovative LENZING Lyocell Dry fiber family at tabletop 202 during the Hygienix Conference, November 18-21, 2024. Facts and figures: LENZING Lyocell Dry fine has a linear density of 1.3dtex; LENZING Lyocell Dry standard has a linear density of 1.7dtex; Fabrics produced using LENZING Lyocell Dry fine and standard have the same basis weight (eg. 50gsm) but the "fine" material has a higher density with up to 30% more fibers in the same space. LENZING Lyocell Dry coarse has a linear density of 6.3dtex.分析記事 • Nov 01Lenzing (VIE:LNZ) Might Be Having Difficulty Using Its Capital EffectivelyWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...お知らせ • Oct 17+ 2 more updatesLenzing Aktiengesellschaft to Report Q3, 2025 Results on Nov 06, 2025Lenzing Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 06, 2025分析記事 • Sep 20Is Lenzing (VIE:LNZ) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Major Estimate Revision • Sep 01Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -€1.87 to -€2.07 per share. Revenue forecast unchanged at €2.65b. Chemicals industry in Austria expected to see average net income growth of 30% next year. Consensus price target broadly unchanged at €34.04. Share price fell 3.0% to €30.85 over the past week.お知らせ • Aug 22Lenzing Aktiengesellschaft Announces CEO ChangesLenzing Aktiengesellschaft announced Stephan Sielaff to leave the company as of August 31, 2024. Rohit Aggarwal will take over the position of CEO as of 1 September 2024. Outgoing Chief Executive Officer Stephan Sielaff will leave the company end of August 2024, by mutual agreement with the Supervisory Board.Major Estimate Revision • Aug 14Consensus EPS estimates fall by 29%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from €2.63b to €2.66b. Forecast EPS reduced from -€1.46 to -€1.87 per share. Chemicals industry in Austria expected to see average net income growth of 30% next year. Consensus price target broadly unchanged at €34.06. Share price was steady at €30.45 over the past week.Reported Earnings • Aug 08Second quarter 2024 earnings released: €1.01 loss per share (vs €0.89 loss in 2Q 2023)Second quarter 2024 results: €1.01 loss per share (further deteriorated from €0.89 loss in 2Q 2023). Revenue: €652.3m (up 4.0% from 2Q 2023). Net loss: €39.0m (loss widened 65% from 2Q 2023). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.分析記事 • Jul 16Lenzing Aktiengesellschaft's (VIE:LNZ) Share Price Is Matching Sentiment Around Its RevenuesLenzing Aktiengesellschaft's ( VIE:LNZ ) price-to-sales (or "P/S") ratio of 0.5x may look like a pretty appealing...分析記事 • Jun 09Lenzing (VIE:LNZ) Has Debt But No Earnings; Should You Worry?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Price Target Changed • May 14Price target increased by 9.6% to €34.26Up from €31.26, the current price target is an average from 5 analysts. New target price is 5.2% below last closing price of €36.15. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €1.46 next year compared to a net loss per share of €20.02 last year.Reported Earnings • May 09First quarter 2024 earnings released: €0.83 loss per share (vs €3.03 loss in 1Q 2023)First quarter 2024 results: €0.83 loss per share (improved from €3.03 loss in 1Q 2023). Revenue: €658.4m (up 5.7% from 1Q 2023). Net loss: €32.0m (loss narrowed 60% from 1Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.分析記事 • Apr 16Lenzing Aktiengesellschaft (VIE:LNZ) Stock Catapults 26% Though Its Price And Business Still Lag The IndustryLenzing Aktiengesellschaft ( VIE:LNZ ) shares have had a really impressive month, gaining 26% after a shaky period...Major Estimate Revision • Mar 22Consensus EPS estimates fall by 138%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -€0.659 to -€1.57 per share. Revenue forecast unchanged at €2.58b. Chemicals industry in Austria expected to see average net income growth of 19% next year. Consensus price target down from €36.21 to €32.26. Share price was steady at €30.10 over the past week.Price Target Changed • Mar 18Price target decreased by 17% to €32.66Down from €39.20, the current price target is an average from 5 analysts. New target price is 31% above last closing price of €24.85. Stock is down 60% over the past year. The company is forecast to post a net loss per share of €0.30 next year compared to a net loss per share of €20.02 last year.Reported Earnings • Mar 15Full year 2023 earnings released: €20.02 loss per share (vs €2.75 loss in FY 2022)Full year 2023 results: €20.02 loss per share (further deteriorated from €2.75 loss in FY 2022). Revenue: €2.52b (down 1.7% from FY 2022). Net loss: €649.4m (loss widened €576.4m from FY 2022). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.Price Target Changed • Feb 29Price target decreased by 10% to €36.66Down from €40.80, the current price target is an average from 5 analysts. New target price is 27% above last closing price of €28.95. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €9.69 next year compared to a net loss per share of €2.75 last year.分析記事 • Feb 27Is Lenzing (VIE:LNZ) Using Debt In A Risky Way?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Major Estimate Revision • Feb 09Consensus EPS estimates fall by 28%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€7.59 to -€9.69 per share. Revenue forecast of €2.46b unchanged since last update. Chemicals industry in Austria expected to see average net income growth of 14% next year. Consensus price target down from €40.80 to €39.20. Share price fell 6.3% to €28.15 over the past week.お知らせ • Feb 01Lenzing Group Teams Up with Recyc Leather and Ganni to Unveil New Footwear MaterialsLenzing Group has partnered with leather alternative expert Recyc Leather to introduce Pelinova, an innovative material that fuses TENCEL™? Lyocell fibers and recycled leather fibers for high-end fashion applications. Joining forces with Danish advanced contemporary brand GANNI, this dynamic trio is set to bring this next-generation material to the market as an alternative to genuine leather materials, starting with GANNI's Slouchy Boots launching early this year. Pelinova: a hybrid alternative combining TENCEL™? L Tokyocell fibers and recycled leather fibers. Recyc Leather's next-generation material, Pelinova®?, is created through a unique, transparent process which involves collecting pre-consumer recycled leather and then hydro-jetting the leather fibers into the TENCEL™? Lanocell fibers, a standout material within the TENCEL™? brand portfolio that is produced from a resource-saving, closed-loop production process. TENCEL™? Liocell fibers are also unfavorable to odor-causing bacteria. The combined efforts between Lenzing and Recyc Leather result in a material which is supple, flexible, and durable, with a low environmental impact utilizing 70% less water than traditional methods and reducing CO2 emissions. Riding on this exciting breakthrough in footwear, Recyc Leather is also exploring the possibility of expanding the fabric application to other leather goods spanning home textiles, furniture, automobile interiors and the luxury segment. Elevating the GANNI partnership: GANNI is a B Corp. certified company, on a journey to become the most responsible version of itself. They believe it's a moral obligation to do better every day. GANNI is committed to minimizing social and environmental impact within its business operation with a goal to reach 50% absolute carbon reduction by 2027, with materials and innovation among its key pillars in reaching this target. In addition to footwear, GANNI sees the application of Recyc Leather's Pelinova®? with TENCEL™? Lycell fibers in the accessories category. GANNI, Recyc Leather, and Lenzing have future developments in the pipeline to get even closer to being able to scale the use of the material. During Premiere Vision Paris (PV Paris, February 6-8), Lenzing will be joined by Recyc Leather and GANNI at a panel discussion to share their collaborative experiences as a prime example of how companies can unite to create high-end fashion using responsibly produced recycled materials. For more interactive participation, visit the TENCEL™? brands at Booth 6D67 and Recyc Leather at Booth 6HUB11. Savings consider solvent recovery. The responsible production of TENCEL™? LTokcell and Modal fibers uses at least 50% less water and emits at least 50% less water. The responsible production of TENEL™? Lyocell and Modal fibers uses At least 50% less water and emissions at least 50% less water, and emits at least 50% more water.Major Estimate Revision • Jan 25Consensus EPS estimates fall by 59%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€4.24 to -€6.73 per share. Revenue forecast unchanged at €2.46b. Chemicals industry in Austria expected to see average net income growth of 1.1% next year. Consensus price target down from €43.60 to €40.80. Share price was steady at €30.00 over the past week.分析記事 • Jan 04Lenzing Aktiengesellschaft's (VIE:LNZ) Low P/S No Reason For ExcitementWhen you see that almost half of the companies in the Chemicals industry in Austria have price-to-sales ratios (or...Major Estimate Revision • Dec 29Consensus EPS estimates fall by 19%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €2.51b to €2.46b. Losses expected to increase from €3.58 per share to €4.24. Chemicals industry in Austria expected to see average net income growth of 3.9% next year. Consensus price target down from €44.60 to €43.60. Share price fell 2.3% to €35.55 over the past week.分析記事 • Nov 10Is Lenzing (VIE:LNZ) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Nov 07New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (5.4% average weekly change). Minor Risk Shareholders have been diluted in the past year (45% increase in shares outstanding).Reported Earnings • Nov 05Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: €0.97 loss per share (further deteriorated from €0.20 loss in 3Q 2022). Revenue: €615.5m (down 9.0% from 3Q 2022). Net loss: €44.3m (loss widened €39.0m from 3Q 2022). Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Oct 12Consensus estimates of losses per share improve by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €2.52b to €2.56b. EPS estimate increased from -€2.96 per share to -€2.55 per share. Chemicals industry in Austria expected to see average net income growth of 4.3% next year. Consensus price target of €50.83 unchanged from last update. Share price rose 4.0% to €38.05 over the past week.お知らせ • Aug 22+ 4 more updatesLenzing Aktiengesellschaft to Report Q3, 2024 Results on Nov 07, 2024Lenzing Aktiengesellschaft announced that they will report Q3, 2024 results on Nov 07, 2024Price Target Changed • Aug 04Price target decreased by 7.7% to €57.24Down from €62.04, the current price target is an average from 5 analysts. New target price is 33% above last closing price of €42.95. Stock is down 48% over the past year. The company is forecast to post a net loss per share of €2.80 next year compared to a net loss per share of €2.75 last year.Reported Earnings • Aug 03Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: €0.89 loss per share (down from €1.49 profit in 2Q 2022). Revenue: €627.1m (down 7.6% from 2Q 2022). Net loss: €23.7m (down 160% from profit in 2Q 2022). Revenue missed analyst estimates by 21%. Earnings per share (EPS) exceeded analyst estimates by 7.3%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.New Risk • Jul 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 45% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (7.1% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 171% Paying a dividend despite having no free cash flows. Minor Risk Shareholders have been diluted in the past year (45% increase in shares outstanding).お知らせ • Jul 07Lenzing Aktiengesellschaft has completed a Follow-on Equity Offering in the amount of €399.456758 million.Lenzing Aktiengesellschaft has completed a Follow-on Equity Offering in the amount of €399.456758 million. Security Name: Shares Security Type: Common Stock Securities Offered: 12,068,180 Price\Range: €33.1 Transaction Features: Rights Offering分析記事 • Jun 16Is Lenzing (VIE:LNZ) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • May 03First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: €3.03 loss per share (down from €0.87 profit in 1Q 2022). Revenue: €623.1m (up 1.3% from 1Q 2022). Net loss: €80.5m (down 450% from profit in 1Q 2022). Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) also missed analyst estimates by 73%. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Major Estimate Revision • Mar 26Consensus EPS estimates fall by 121%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€0.18 to -€0.397 per share. Revenue forecast unchanged at €2.65b. Chemicals industry in Austria expected to see average net income decline 2.1% next year. Consensus price target up from €60.80 to €65.04. Share price fell 4.6% to €61.90 over the past week.分析記事 • Mar 22Lenzing Aktiengesellschaft's (VIE:LNZ) Intrinsic Value Is Potentially 81% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, Lenzing fair value estimate is €117 Current share price of...Major Estimate Revision • Mar 16Consensus EPS estimates fall from profit to €0.18 lossThe consensus outlook for fiscal year 2023 has been updated. Expected to report loss instead of -€0.18 instead of €0.088 per share profit previously forecast. Revenue forecast unchanged at €2.64b Chemicals industry in Austria expected to see average net income decline 0.3% next year. Consensus price target of €60.80 unchanged from last update. Share price fell 10% to €64.80 over the past week.Reported Earnings • Mar 12Full year 2022 earnings released: €2.75 loss per share (vs €4.16 profit in FY 2021)Full year 2022 results: €2.75 loss per share (down from €4.16 profit in FY 2021). Revenue: €2.57b (up 17% from FY 2021). Net loss: €73.1m (down 166% from profit in FY 2021). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.Price Target Changed • Mar 09Price target decreased by 18% to €60.80Down from €74.30, the current price target is an average from 5 analysts. New target price is 16% below last closing price of €72.30. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €1.07 compared to earnings per share of €4.16 last year.Major Estimate Revision • Mar 01Consensus EPS estimates fall by 74%The consensus outlook for fiscal year 2022 has been updated. 2022 expected loss increased from -€0.442 to -€0.77 per share. Revenue forecast unchanged at €2.49b. Chemicals industry in Austria expected to see average net income growth of 0.2% next year. Consensus price target broadly unchanged at €74.64. Share price was steady at €70.50 over the past week.分析記事 • Feb 15Here's Why Lenzing (VIE:LNZ) Is Weighed Down By Its Debt LoadLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Feb 02Is There Now An Opportunity In Lenzing Aktiengesellschaft (VIE:LNZ)?Lenzing Aktiengesellschaft ( VIE:LNZ ), is not the largest company out there, but it received a lot of attention from a...分析記事 • Jan 20Capital Allocation Trends At Lenzing (VIE:LNZ) Aren't IdealTo find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 20% share price gain to €65.80, the stock trades at a forward P/E ratio of 577x. Average forward P/E is 16x in the Chemicals industry in Europe. Total loss to shareholders of 16% over the past three years.Major Estimate Revision • Dec 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from €0.87 to €0.23 per share. Revenue forecast steady at €2.54b. Net income forecast to shrink 83% next year vs 2.5% decline forecast for Chemicals industry in Austria. Consensus price target of €73.90 unchanged from last update. Share price fell 15% to €56.50 over the past week.Valuation Update With 7 Day Price Move • Dec 20Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to €54.20, the stock trades at a forward P/E ratio of 91x. Average forward P/E is 16x in the Chemicals industry in Europe. Total loss to shareholders of 33% over the past three years.Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from €1.63 to €0.95 per share. Revenue forecast steady at €2.54b. Net income forecast to shrink 71% next year vs 2.8% growth forecast for Chemicals industry in Austria . Consensus price target down from €78.30 to €73.90. Share price was steady at €68.40 over the past week.Reported Earnings • Nov 05Third quarter 2022 earnings released: €0.20 loss per share (vs €0.71 profit in 3Q 2021)Third quarter 2022 results: €0.20 loss per share (down from €0.71 profit in 3Q 2021). Revenue: €676.5m (up 22% from 3Q 2021). Net loss: €5.30m (down 128% from profit in 3Q 2021). Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Nov 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to €55.60, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 15x in the Chemicals industry in Europe. Total loss to shareholders of 38% over the past three years.お知らせ • Nov 03Lenzing AG Appoints Nico Reiner as Chief Financial OfficerThe Supervisory Board of Lenzing AG, has appointed Nico Reiner as its new Chief Financial Officer. Mr. Reiner will join Lenzing's Managing Board led by Chief Executive Officer Stephan Sielaff on January 1, 2023. He will succeed Chief Financial Officer Thomas Obendrauf, who is leaving the company of his own volition after seven years. Nico Reiner has held several positions in his professional career to date, including CFO at globally operating companies such as Schüco Group, AL-KO Group and Pfleiderer Group, as well as management consultant roles. His most recent appointment was as CFO of Vacuumschmelze GmbH & Co. KG, a global player with headquarters in Hanau that specializes in the development, production and marketing of magnetic materials. Born in Grünwald near Munich, Mr. Reiner graduated from the University of Regensburg with a degree in business administration and has a doctorate from HHL Leipzig Graduate School of Management. Chief Financial Officer Thomas Obendrauf notified the Supervisory Board in March that he would not be extending his contract when it came to an end inJune 2022 as after seven years at Lenzing, he is leaving to pursue a career change. Until Mr. Reiner joins the company, Stephan Sielaff will continue to assume the role of CFO on an interim basis, with Mr. Obendrauf supporting the company in an advisory capacity.お知らせ • Oct 28+ 4 more updatesLenzing Aktiengesellschaft to Report Q3, 2023 Results on Nov 03, 2023Lenzing Aktiengesellschaft announced that they will report Q3, 2023 results on Nov 03, 2023分析記事 • Oct 28What Is Lenzing Aktiengesellschaft's (VIE:LNZ) Share Price Doing?Lenzing Aktiengesellschaft ( VIE:LNZ ), might not be a large cap stock, but it received a lot of attention from a...Price Target Changed • Oct 05Price target decreased to €107Down from €127, the current price target is an average from 5 analysts. New target price is 104% above last closing price of €52.20. Stock is down 49% over the past year. The company is forecast to post earnings per share of €5.10 for next year compared to €4.16 last year.業績と収益の成長予測WBAG:LNZ - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20282,787-23194337312/31/20272,708-41236312512/31/20262,651-71176258412/31/20252,602-210279420N/A9/30/20252,678-191131288N/A6/30/20252,694-12175233N/A3/31/20252,696-12093249N/A12/31/20242,664-157241395N/A9/30/20242,614-636257419N/A6/30/20242,582-616238429N/A3/31/20242,556-601112329N/A12/31/20232,521-649-108160N/A9/30/20232,461-279-384-17N/A6/30/20232,522-240-534-88N/A3/31/20232,574-177-772-171N/A12/31/20222,566-73-742-43N/A9/30/20222,57668-624121N/A6/30/20222,45592-598209N/A3/31/20222,320105-453362N/A12/31/20212,195110-450394N/A9/30/20212,026109-479371N/A6/30/20211,85686-560266N/A3/31/20211,65612-613129N/A12/31/20201,6336-62049N/A9/30/20201,7023-47460N/A6/30/20201,86046-314103N/A3/31/20202,058101-134203N/A12/31/20192,1621231245N/A9/30/20192,210132N/A204N/A6/30/20192,240136N/A246N/A3/31/20192,236143N/A245N/A12/31/20182,232149N/A280N/A9/30/20182,222197N/A256N/A6/30/20182,240222N/A228N/A3/31/20182,275255N/A274N/A12/31/20172,305278N/A271N/A9/30/20172,318282N/A361N/A6/30/20172,278280N/A406N/A3/31/20172,232255N/A475N/A12/31/20162,156225N/A473N/A9/30/20162,123200N/A405N/A6/30/20162,084167N/A385N/A3/31/20162,044153N/A282N/A12/31/20152,006127N/A216N/A9/30/20151,99128N/A245N/A6/30/20151,94424N/A215N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: LNZ今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: LNZ今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: LNZ今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: LNZの収益 ( 1.9% ) Austrian市場 ( 3.5% ) よりも低い成長が予測されています。高い収益成長: LNZの収益 ( 1.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: LNZ 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 10:36終値2026/05/07 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Lenzing Aktiengesellschaft 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Sebastian BrayBerenbergFabio LopesBofA Global ResearchLars Vom-CleffDeutsche Bank7 その他のアナリストを表示
Price Target Changed • Apr 07Price target decreased by 10.0% to €23.50Down from €26.10, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of €23.05. Stock is down 4.4% over the past year. The company is forecast to post a net loss per share of €1.83 next year compared to a net loss per share of €5.45 last year.
Major Estimate Revision • Feb 18Consensus EPS estimates fall by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€3.34 to -€3.88 per share. Revenue forecast unchanged at €2.62b. Chemicals industry in Austria expected to see average net income growth of 29% next year. Consensus price target broadly unchanged at €26.10. Share price fell 5.8% to €26.10 over the past week.
Breakeven Date Change • Feb 17No longer forecast to breakevenThe 5 analysts covering Lenzing no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €49.9m in 2027. New consensus forecast suggests the company will make a loss of €60.8m in 2027.
Price Target Changed • Dec 29Price target decreased by 11% to €24.50Down from €27.40, the current price target is an average from 4 analysts. New target price is 8.9% above last closing price of €22.50. Stock is down 24% over the past year. The company is forecast to post a net loss per share of €3.34 next year compared to a net loss per share of €4.06 last year.
Major Estimate Revision • Oct 01Consensus EPS estimates fall by 38%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€1.37 to -€1.89 per share. Revenue forecast of €2.69b unchanged since last update. Chemicals industry in Austria expected to see average net income growth of 17% next year. Consensus price target broadly unchanged at €28.20. Share price fell 3.7% to €25.80 over the past week.
Major Estimate Revision • Aug 15Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.988 to -€1.10 per share. Revenue forecast unchanged at €2.69b. Chemicals industry in Austria expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at €28.60. Share price fell 5.5% to €26.75 over the past week.
Price Target Changed • Apr 07Price target decreased by 10.0% to €23.50Down from €26.10, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of €23.05. Stock is down 4.4% over the past year. The company is forecast to post a net loss per share of €1.83 next year compared to a net loss per share of €5.45 last year.
Reported Earnings • Mar 20Full year 2025 earnings released: €5.45 loss per share (vs €4.06 loss in FY 2024)Full year 2025 results: €5.45 loss per share (further deteriorated from €4.06 loss in FY 2024). Revenue: €2.60b (down 2.3% from FY 2024). Net loss: €210.3m (loss widened 34% from FY 2024). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Feb 18Consensus EPS estimates fall by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€3.34 to -€3.88 per share. Revenue forecast unchanged at €2.62b. Chemicals industry in Austria expected to see average net income growth of 29% next year. Consensus price target broadly unchanged at €26.10. Share price fell 5.8% to €26.10 over the past week.
Breakeven Date Change • Feb 17No longer forecast to breakevenThe 5 analysts covering Lenzing no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €49.9m in 2027. New consensus forecast suggests the company will make a loss of €60.8m in 2027.
お知らせ • Feb 03Lenzing Aktiengesellschaft (WBAG:LNZ) acquired an additional unknown minority stake in TreeToTextile AB.Lenzing Aktiengesellschaft (WBAG:LNZ) acquired an additional unknown minority stake in TreeToTextile AB on February 2, 2026. The transaction is executed through the issuance of new shares. After the acquisition Lenzing Aktiengesellschaft will own majority stake in TreeToTextile AB. Lenzing Aktiengesellschaft (WBAG:LNZ) completed the acquisition of additional unknown minority stake in TreeToTextile AB on February 2, 2026.
Price Target Changed • Dec 29Price target decreased by 11% to €24.50Down from €27.40, the current price target is an average from 4 analysts. New target price is 8.9% above last closing price of €22.50. Stock is down 24% over the past year. The company is forecast to post a net loss per share of €3.34 next year compared to a net loss per share of €4.06 last year.
お知らせ • Dec 09Lenzing Aktiengesellschaft, Annual General Meeting, Apr 23, 2026Lenzing Aktiengesellschaft, Annual General Meeting, Apr 23, 2026.
Major Estimate Revision • Oct 01Consensus EPS estimates fall by 38%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€1.37 to -€1.89 per share. Revenue forecast of €2.69b unchanged since last update. Chemicals industry in Austria expected to see average net income growth of 17% next year. Consensus price target broadly unchanged at €28.20. Share price fell 3.7% to €25.80 over the past week.
お知らせ • Sep 02+ 3 more updatesLenzing Aktiengesellschaft to Report Q1, 2026 Results on May 07, 2026Lenzing Aktiengesellschaft announced that they will report Q1, 2026 results on May 07, 2026
Major Estimate Revision • Aug 15Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.988 to -€1.10 per share. Revenue forecast unchanged at €2.69b. Chemicals industry in Austria expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at €28.60. Share price fell 5.5% to €26.75 over the past week.
Price Target Changed • Aug 12Price target decreased by 8.9% to €28.50Down from €31.28, the current price target is an average from 5 analysts. New target price is 7.5% above last closing price of €26.50. Stock is down 13% over the past year. The company is forecast to post a net loss per share of €1.16 next year compared to a net loss per share of €4.06 last year.
Reported Earnings • Aug 08Second quarter 2025 earnings released: €1.02 loss per share (vs €1.01 loss in 2Q 2024)Second quarter 2025 results: €1.02 loss per share (further deteriorated from €1.01 loss in 2Q 2024). Revenue: €650.9m (flat on 2Q 2024). Net loss: €39.4m (loss widened 1.0% from 2Q 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 31% per year and the company’s share price has also fallen by 31% per year.
分析記事 • Aug 01Returns On Capital At Lenzing (VIE:LNZ) Paint A Concerning PictureDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
Major Estimate Revision • Jul 09Consensus EPS estimates fall by 18%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.835 to -€0.988 per share. Revenue forecast unchanged at €2.69b. Chemicals industry in Austria expected to see average net income growth of 20% next year. Consensus price target broadly unchanged at €30.95. Share price rose 2.8% to €25.50 over the past week.
分析記事 • Jul 09Lenzing Aktiengesellschaft's (VIE:LNZ) Low P/S No Reason For ExcitementWhen close to half the companies operating in the Chemicals industry in Austria have price-to-sales ratios (or "P/S...
Price Target Changed • Jul 08Price target decreased by 7.5% to €30.95Down from €33.45, the current price target is an average from 6 analysts. New target price is 23% above last closing price of €25.10. Stock is down 24% over the past year. The company is forecast to post a net loss per share of €0.99 next year compared to a net loss per share of €4.06 last year.
Major Estimate Revision • Jun 17Consensus EPS estimates fall by 38%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.604 to -€0.835 per share. Revenue forecast unchanged at €2.70b. Chemicals industry in Austria expected to see average net income growth of 18% next year. Consensus price target down from €33.45 to €31.28. Share price fell 12% to €23.75 over the past week.
分析記事 • Jun 12Does Lenzing (VIE:LNZ) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Major Estimate Revision • Jun 01Consensus EPS estimates fall by 25%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.484 to -€0.604 per share. Revenue forecast unchanged at €2.72b. Chemicals industry in Austria expected to see average net income growth of 17% next year. Consensus price target of €33.45 unchanged from last update. Share price was steady at €26.40 over the past week.
Reported Earnings • May 13First quarter 2025 earnings released: EPS: €0.12 (vs €0.83 loss in 1Q 2024)First quarter 2025 results: EPS: €0.12 (up from €0.83 loss in 1Q 2024). Revenue: €690.2m (up 4.8% from 1Q 2024). Net income: €4.70m (up €36.7m from 1Q 2024). Profit margin: 0.7% (up from net loss in 1Q 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 18Lenzing Announces Supervisory Board ChangesLenzing at its annual general meeting, appointed Patrick Lackenbucher and Leonardo Grimaldi to the supervisory board until 2029. They replace Cord Prinzhorn, whose term expired, and Marcelo Feriozzi Bacci, who resigned from the board in December 2024, according to a company statement on Thursday.
分析記事 • Apr 14Returns On Capital Signal Tricky Times Ahead For Lenzing (VIE:LNZ)If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
お知らせ • Apr 03The Lenzing Group Announces Board Member and Chief Transformation Officer Walter Bickel Will Leave Company At the End of March 2025The Lenzing Group announced personnel changes in the company’s Managing Board. The Supervisory Board of Lenzing AG and Dr. Walter Bickel, Chief Transformation Officer of Lenzing AG, have mutually agreed to end the temporary mandate of Mr. Bickel and that Mr. Bickel will step down from his operational activities at the end of March 2025. Mr. Bickel was appointed to the Managing Board of Lenzing AG as of April 15, 2024 to strengthen the Lenzing Managing Board and to be responsible for the further development and implementation of the performance program. Under his leadership, a significant overachievement of the planned contributions from the performance program could be realized. The basis for future significant improvement steps is established, and the program has been structured in a way that it can now be continued by Lenzing AG seamlessly.
Major Estimate Revision • Apr 02Consensus EPS estimates upgraded to €0.49 lossThe consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -€0.64 to -€0.487 per share. Revenue forecast steady at €2.72b. Chemicals industry in Austria expected to see average net income growth of 17% next year. Consensus price target broadly unchanged at €32.95. Share price fell 15% to €25.90 over the past week.
分析記事 • Mar 15Lenzing Aktiengesellschaft (VIE:LNZ) Surges 35% Yet Its Low P/S Is No Reason For ExcitementLenzing Aktiengesellschaft ( VIE:LNZ ) shares have had a really impressive month, gaining 35% after a shaky period...
Reported Earnings • Mar 14Full year 2024 earnings released: €4.06 loss per share (vs €20.02 loss in FY 2023)Full year 2024 results: €4.06 loss per share (improved from €20.02 loss in FY 2023). Revenue: €2.66b (up 5.7% from FY 2023). Net loss: €156.6m (loss narrowed 76% from FY 2023). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 12Cord Prinzhorn Not Stand for Re-Election as Member of Lenzing AG's Supervisory BoardThe Chairman of the Supervisory Board of Lenzing AG, Cord Prinzhorn, has informed the Nomination Committee of the Supervisory Board that he will not extend his term as a member of the company’s Supervisory Board after the Annual General Meeting on April 17, 2025 and will not stand for re-election at the upcoming Annual General Meeting. Cord Prinzhorn intends to devote more time to his existing and new activities at the B&C Group. Mr. Prinzhorn will thus leave the Supervisory Board of Lenzing AG at the end of the Annual General Meeting.
New Risk • Feb 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Austrian stocks, typically moving 6.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (6.0% average weekly change).
お知らせ • Jan 27Lenzing Aktiengesellschaft, Annual General Meeting, Apr 17, 2025Lenzing Aktiengesellschaft, Annual General Meeting, Apr 17, 2025.
分析記事 • Jan 14Is Lenzing (VIE:LNZ) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Austrian stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (4.6% average weekly change).
分析記事 • Dec 06Investors Don't See Light At End Of Lenzing Aktiengesellschaft's (VIE:LNZ) TunnelWhen you see that almost half of the companies in the Chemicals industry in Austria have price-to-sales ratios (or...
Major Estimate Revision • Nov 14Consensus EPS estimates fall by 34%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -€2.63 to -€3.51 per share. Revenue forecast unchanged at €2.66b. Chemicals industry in Austria expected to see average net income growth of 35% next year. Consensus price target broadly unchanged at €33.74. Share price fell 5.6% to €29.75 over the past week.
Reported Earnings • Nov 08Third quarter 2024 earnings released: €1.66 loss per share (vs €0.97 loss in 3Q 2023)Third quarter 2024 results: €1.66 loss per share (further deteriorated from €0.97 loss in 3Q 2023). Revenue: €647.5m (up 5.2% from 3Q 2023). Net loss: €64.1m (loss widened 45% from 3Q 2023). Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 06Lenzing Nonwovens Expands its LENZING Lyocell Dry Fiber Portfolio to Offer Cellulosic Solutions for a Wider Range of ApplicationsLenzing Nonwovens announced the expansion of its LENZING Lyocell Dry fiber portfolio with two new cellulosic fibers – a fine dry fiber that delivers strength and softness and a coarse dry fiber which provides enhanced liquid and air flow. These two innovative products enable customers to confidently broaden their use of LENZING's wood-based and biodegradable fibers into a wider range of applications while maintaining exceptional performance. All LENZING Lyocell Dry fibers within the family (standard, fine, and coarse) have hydrophobic properties which ensure efficient liquid management suitable for extensive nonwoven applications. The new LENZING Lyocell Dry fine fiber can produce nonwoven fabrics with higher density compared to LENZING Lyocell Dry standard fiber. With up to 30% more cellulosic fibers in the same space, customers can create strong and soft nonwoven products. These fibers are suitable for use in hygiene applications such as diapers or sanitary pads. The new LENZING Lyocell Dry coarse fiber creates fabrics that are more open due to its extended fiber diameter, and thus increasing the pore sizes between the fibers in the fabric. This allows for more air or liquid to flow through the material. It is particularly suitable for the acquisition and distribution layer in hygiene products and is also being explored for industrial filtration applications. Lenzing will showcase its innovative LENZING Lyocell Dry fiber family at tabletop 202 during the Hygienix Conference, November 18-21, 2024. Facts and figures: LENZING Lyocell Dry fine has a linear density of 1.3dtex; LENZING Lyocell Dry standard has a linear density of 1.7dtex; Fabrics produced using LENZING Lyocell Dry fine and standard have the same basis weight (eg. 50gsm) but the "fine" material has a higher density with up to 30% more fibers in the same space. LENZING Lyocell Dry coarse has a linear density of 6.3dtex.
分析記事 • Nov 01Lenzing (VIE:LNZ) Might Be Having Difficulty Using Its Capital EffectivelyWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
お知らせ • Oct 17+ 2 more updatesLenzing Aktiengesellschaft to Report Q3, 2025 Results on Nov 06, 2025Lenzing Aktiengesellschaft announced that they will report Q3, 2025 results on Nov 06, 2025
分析記事 • Sep 20Is Lenzing (VIE:LNZ) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Major Estimate Revision • Sep 01Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -€1.87 to -€2.07 per share. Revenue forecast unchanged at €2.65b. Chemicals industry in Austria expected to see average net income growth of 30% next year. Consensus price target broadly unchanged at €34.04. Share price fell 3.0% to €30.85 over the past week.
お知らせ • Aug 22Lenzing Aktiengesellschaft Announces CEO ChangesLenzing Aktiengesellschaft announced Stephan Sielaff to leave the company as of August 31, 2024. Rohit Aggarwal will take over the position of CEO as of 1 September 2024. Outgoing Chief Executive Officer Stephan Sielaff will leave the company end of August 2024, by mutual agreement with the Supervisory Board.
Major Estimate Revision • Aug 14Consensus EPS estimates fall by 29%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from €2.63b to €2.66b. Forecast EPS reduced from -€1.46 to -€1.87 per share. Chemicals industry in Austria expected to see average net income growth of 30% next year. Consensus price target broadly unchanged at €34.06. Share price was steady at €30.45 over the past week.
Reported Earnings • Aug 08Second quarter 2024 earnings released: €1.01 loss per share (vs €0.89 loss in 2Q 2023)Second quarter 2024 results: €1.01 loss per share (further deteriorated from €0.89 loss in 2Q 2023). Revenue: €652.3m (up 4.0% from 2Q 2023). Net loss: €39.0m (loss widened 65% from 2Q 2023). Revenue is forecast to grow 2.7% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
分析記事 • Jul 16Lenzing Aktiengesellschaft's (VIE:LNZ) Share Price Is Matching Sentiment Around Its RevenuesLenzing Aktiengesellschaft's ( VIE:LNZ ) price-to-sales (or "P/S") ratio of 0.5x may look like a pretty appealing...
分析記事 • Jun 09Lenzing (VIE:LNZ) Has Debt But No Earnings; Should You Worry?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Price Target Changed • May 14Price target increased by 9.6% to €34.26Up from €31.26, the current price target is an average from 5 analysts. New target price is 5.2% below last closing price of €36.15. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €1.46 next year compared to a net loss per share of €20.02 last year.
Reported Earnings • May 09First quarter 2024 earnings released: €0.83 loss per share (vs €3.03 loss in 1Q 2023)First quarter 2024 results: €0.83 loss per share (improved from €3.03 loss in 1Q 2023). Revenue: €658.4m (up 5.7% from 1Q 2023). Net loss: €32.0m (loss narrowed 60% from 1Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
分析記事 • Apr 16Lenzing Aktiengesellschaft (VIE:LNZ) Stock Catapults 26% Though Its Price And Business Still Lag The IndustryLenzing Aktiengesellschaft ( VIE:LNZ ) shares have had a really impressive month, gaining 26% after a shaky period...
Major Estimate Revision • Mar 22Consensus EPS estimates fall by 138%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -€0.659 to -€1.57 per share. Revenue forecast unchanged at €2.58b. Chemicals industry in Austria expected to see average net income growth of 19% next year. Consensus price target down from €36.21 to €32.26. Share price was steady at €30.10 over the past week.
Price Target Changed • Mar 18Price target decreased by 17% to €32.66Down from €39.20, the current price target is an average from 5 analysts. New target price is 31% above last closing price of €24.85. Stock is down 60% over the past year. The company is forecast to post a net loss per share of €0.30 next year compared to a net loss per share of €20.02 last year.
Reported Earnings • Mar 15Full year 2023 earnings released: €20.02 loss per share (vs €2.75 loss in FY 2022)Full year 2023 results: €20.02 loss per share (further deteriorated from €2.75 loss in FY 2022). Revenue: €2.52b (down 1.7% from FY 2022). Net loss: €649.4m (loss widened €576.4m from FY 2022). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
Price Target Changed • Feb 29Price target decreased by 10% to €36.66Down from €40.80, the current price target is an average from 5 analysts. New target price is 27% above last closing price of €28.95. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €9.69 next year compared to a net loss per share of €2.75 last year.
分析記事 • Feb 27Is Lenzing (VIE:LNZ) Using Debt In A Risky Way?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Major Estimate Revision • Feb 09Consensus EPS estimates fall by 28%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€7.59 to -€9.69 per share. Revenue forecast of €2.46b unchanged since last update. Chemicals industry in Austria expected to see average net income growth of 14% next year. Consensus price target down from €40.80 to €39.20. Share price fell 6.3% to €28.15 over the past week.
お知らせ • Feb 01Lenzing Group Teams Up with Recyc Leather and Ganni to Unveil New Footwear MaterialsLenzing Group has partnered with leather alternative expert Recyc Leather to introduce Pelinova, an innovative material that fuses TENCEL™? Lyocell fibers and recycled leather fibers for high-end fashion applications. Joining forces with Danish advanced contemporary brand GANNI, this dynamic trio is set to bring this next-generation material to the market as an alternative to genuine leather materials, starting with GANNI's Slouchy Boots launching early this year. Pelinova: a hybrid alternative combining TENCEL™? L Tokyocell fibers and recycled leather fibers. Recyc Leather's next-generation material, Pelinova®?, is created through a unique, transparent process which involves collecting pre-consumer recycled leather and then hydro-jetting the leather fibers into the TENCEL™? Lanocell fibers, a standout material within the TENCEL™? brand portfolio that is produced from a resource-saving, closed-loop production process. TENCEL™? Liocell fibers are also unfavorable to odor-causing bacteria. The combined efforts between Lenzing and Recyc Leather result in a material which is supple, flexible, and durable, with a low environmental impact utilizing 70% less water than traditional methods and reducing CO2 emissions. Riding on this exciting breakthrough in footwear, Recyc Leather is also exploring the possibility of expanding the fabric application to other leather goods spanning home textiles, furniture, automobile interiors and the luxury segment. Elevating the GANNI partnership: GANNI is a B Corp. certified company, on a journey to become the most responsible version of itself. They believe it's a moral obligation to do better every day. GANNI is committed to minimizing social and environmental impact within its business operation with a goal to reach 50% absolute carbon reduction by 2027, with materials and innovation among its key pillars in reaching this target. In addition to footwear, GANNI sees the application of Recyc Leather's Pelinova®? with TENCEL™? Lycell fibers in the accessories category. GANNI, Recyc Leather, and Lenzing have future developments in the pipeline to get even closer to being able to scale the use of the material. During Premiere Vision Paris (PV Paris, February 6-8), Lenzing will be joined by Recyc Leather and GANNI at a panel discussion to share their collaborative experiences as a prime example of how companies can unite to create high-end fashion using responsibly produced recycled materials. For more interactive participation, visit the TENCEL™? brands at Booth 6D67 and Recyc Leather at Booth 6HUB11. Savings consider solvent recovery. The responsible production of TENCEL™? LTokcell and Modal fibers uses at least 50% less water and emits at least 50% less water. The responsible production of TENEL™? Lyocell and Modal fibers uses At least 50% less water and emissions at least 50% less water, and emits at least 50% more water.
Major Estimate Revision • Jan 25Consensus EPS estimates fall by 59%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€4.24 to -€6.73 per share. Revenue forecast unchanged at €2.46b. Chemicals industry in Austria expected to see average net income growth of 1.1% next year. Consensus price target down from €43.60 to €40.80. Share price was steady at €30.00 over the past week.
分析記事 • Jan 04Lenzing Aktiengesellschaft's (VIE:LNZ) Low P/S No Reason For ExcitementWhen you see that almost half of the companies in the Chemicals industry in Austria have price-to-sales ratios (or...
Major Estimate Revision • Dec 29Consensus EPS estimates fall by 19%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €2.51b to €2.46b. Losses expected to increase from €3.58 per share to €4.24. Chemicals industry in Austria expected to see average net income growth of 3.9% next year. Consensus price target down from €44.60 to €43.60. Share price fell 2.3% to €35.55 over the past week.
分析記事 • Nov 10Is Lenzing (VIE:LNZ) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Nov 07New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (5.4% average weekly change). Minor Risk Shareholders have been diluted in the past year (45% increase in shares outstanding).
Reported Earnings • Nov 05Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: €0.97 loss per share (further deteriorated from €0.20 loss in 3Q 2022). Revenue: €615.5m (down 9.0% from 3Q 2022). Net loss: €44.3m (loss widened €39.0m from 3Q 2022). Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Oct 12Consensus estimates of losses per share improve by 14%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €2.52b to €2.56b. EPS estimate increased from -€2.96 per share to -€2.55 per share. Chemicals industry in Austria expected to see average net income growth of 4.3% next year. Consensus price target of €50.83 unchanged from last update. Share price rose 4.0% to €38.05 over the past week.
お知らせ • Aug 22+ 4 more updatesLenzing Aktiengesellschaft to Report Q3, 2024 Results on Nov 07, 2024Lenzing Aktiengesellschaft announced that they will report Q3, 2024 results on Nov 07, 2024
Price Target Changed • Aug 04Price target decreased by 7.7% to €57.24Down from €62.04, the current price target is an average from 5 analysts. New target price is 33% above last closing price of €42.95. Stock is down 48% over the past year. The company is forecast to post a net loss per share of €2.80 next year compared to a net loss per share of €2.75 last year.
Reported Earnings • Aug 03Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: €0.89 loss per share (down from €1.49 profit in 2Q 2022). Revenue: €627.1m (down 7.6% from 2Q 2022). Net loss: €23.7m (down 160% from profit in 2Q 2022). Revenue missed analyst estimates by 21%. Earnings per share (EPS) exceeded analyst estimates by 7.3%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
New Risk • Jul 14New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 45% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (7.1% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 171% Paying a dividend despite having no free cash flows. Minor Risk Shareholders have been diluted in the past year (45% increase in shares outstanding).
お知らせ • Jul 07Lenzing Aktiengesellschaft has completed a Follow-on Equity Offering in the amount of €399.456758 million.Lenzing Aktiengesellschaft has completed a Follow-on Equity Offering in the amount of €399.456758 million. Security Name: Shares Security Type: Common Stock Securities Offered: 12,068,180 Price\Range: €33.1 Transaction Features: Rights Offering
分析記事 • Jun 16Is Lenzing (VIE:LNZ) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • May 03First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: €3.03 loss per share (down from €0.87 profit in 1Q 2022). Revenue: €623.1m (up 1.3% from 1Q 2022). Net loss: €80.5m (down 450% from profit in 1Q 2022). Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) also missed analyst estimates by 73%. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Major Estimate Revision • Mar 26Consensus EPS estimates fall by 121%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€0.18 to -€0.397 per share. Revenue forecast unchanged at €2.65b. Chemicals industry in Austria expected to see average net income decline 2.1% next year. Consensus price target up from €60.80 to €65.04. Share price fell 4.6% to €61.90 over the past week.
分析記事 • Mar 22Lenzing Aktiengesellschaft's (VIE:LNZ) Intrinsic Value Is Potentially 81% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, Lenzing fair value estimate is €117 Current share price of...
Major Estimate Revision • Mar 16Consensus EPS estimates fall from profit to €0.18 lossThe consensus outlook for fiscal year 2023 has been updated. Expected to report loss instead of -€0.18 instead of €0.088 per share profit previously forecast. Revenue forecast unchanged at €2.64b Chemicals industry in Austria expected to see average net income decline 0.3% next year. Consensus price target of €60.80 unchanged from last update. Share price fell 10% to €64.80 over the past week.
Reported Earnings • Mar 12Full year 2022 earnings released: €2.75 loss per share (vs €4.16 profit in FY 2021)Full year 2022 results: €2.75 loss per share (down from €4.16 profit in FY 2021). Revenue: €2.57b (up 17% from FY 2021). Net loss: €73.1m (down 166% from profit in FY 2021). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
Price Target Changed • Mar 09Price target decreased by 18% to €60.80Down from €74.30, the current price target is an average from 5 analysts. New target price is 16% below last closing price of €72.30. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €1.07 compared to earnings per share of €4.16 last year.
Major Estimate Revision • Mar 01Consensus EPS estimates fall by 74%The consensus outlook for fiscal year 2022 has been updated. 2022 expected loss increased from -€0.442 to -€0.77 per share. Revenue forecast unchanged at €2.49b. Chemicals industry in Austria expected to see average net income growth of 0.2% next year. Consensus price target broadly unchanged at €74.64. Share price was steady at €70.50 over the past week.
分析記事 • Feb 15Here's Why Lenzing (VIE:LNZ) Is Weighed Down By Its Debt LoadLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Feb 02Is There Now An Opportunity In Lenzing Aktiengesellschaft (VIE:LNZ)?Lenzing Aktiengesellschaft ( VIE:LNZ ), is not the largest company out there, but it received a lot of attention from a...
分析記事 • Jan 20Capital Allocation Trends At Lenzing (VIE:LNZ) Aren't IdealTo find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 20% share price gain to €65.80, the stock trades at a forward P/E ratio of 577x. Average forward P/E is 16x in the Chemicals industry in Europe. Total loss to shareholders of 16% over the past three years.
Major Estimate Revision • Dec 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from €0.87 to €0.23 per share. Revenue forecast steady at €2.54b. Net income forecast to shrink 83% next year vs 2.5% decline forecast for Chemicals industry in Austria. Consensus price target of €73.90 unchanged from last update. Share price fell 15% to €56.50 over the past week.
Valuation Update With 7 Day Price Move • Dec 20Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to €54.20, the stock trades at a forward P/E ratio of 91x. Average forward P/E is 16x in the Chemicals industry in Europe. Total loss to shareholders of 33% over the past three years.
Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from €1.63 to €0.95 per share. Revenue forecast steady at €2.54b. Net income forecast to shrink 71% next year vs 2.8% growth forecast for Chemicals industry in Austria . Consensus price target down from €78.30 to €73.90. Share price was steady at €68.40 over the past week.
Reported Earnings • Nov 05Third quarter 2022 earnings released: €0.20 loss per share (vs €0.71 profit in 3Q 2021)Third quarter 2022 results: €0.20 loss per share (down from €0.71 profit in 3Q 2021). Revenue: €676.5m (up 22% from 3Q 2021). Net loss: €5.30m (down 128% from profit in 3Q 2021). Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Nov 04Investor sentiment improved over the past weekAfter last week's 17% share price gain to €55.60, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 15x in the Chemicals industry in Europe. Total loss to shareholders of 38% over the past three years.
お知らせ • Nov 03Lenzing AG Appoints Nico Reiner as Chief Financial OfficerThe Supervisory Board of Lenzing AG, has appointed Nico Reiner as its new Chief Financial Officer. Mr. Reiner will join Lenzing's Managing Board led by Chief Executive Officer Stephan Sielaff on January 1, 2023. He will succeed Chief Financial Officer Thomas Obendrauf, who is leaving the company of his own volition after seven years. Nico Reiner has held several positions in his professional career to date, including CFO at globally operating companies such as Schüco Group, AL-KO Group and Pfleiderer Group, as well as management consultant roles. His most recent appointment was as CFO of Vacuumschmelze GmbH & Co. KG, a global player with headquarters in Hanau that specializes in the development, production and marketing of magnetic materials. Born in Grünwald near Munich, Mr. Reiner graduated from the University of Regensburg with a degree in business administration and has a doctorate from HHL Leipzig Graduate School of Management. Chief Financial Officer Thomas Obendrauf notified the Supervisory Board in March that he would not be extending his contract when it came to an end inJune 2022 as after seven years at Lenzing, he is leaving to pursue a career change. Until Mr. Reiner joins the company, Stephan Sielaff will continue to assume the role of CFO on an interim basis, with Mr. Obendrauf supporting the company in an advisory capacity.
お知らせ • Oct 28+ 4 more updatesLenzing Aktiengesellschaft to Report Q3, 2023 Results on Nov 03, 2023Lenzing Aktiengesellschaft announced that they will report Q3, 2023 results on Nov 03, 2023
分析記事 • Oct 28What Is Lenzing Aktiengesellschaft's (VIE:LNZ) Share Price Doing?Lenzing Aktiengesellschaft ( VIE:LNZ ), might not be a large cap stock, but it received a lot of attention from a...
Price Target Changed • Oct 05Price target decreased to €107Down from €127, the current price target is an average from 5 analysts. New target price is 104% above last closing price of €52.20. Stock is down 49% over the past year. The company is forecast to post earnings per share of €5.10 for next year compared to €4.16 last year.